Area of research
Epidemiology · Oncology
Research interest
Research interests include Neuroendocrine Tumor Research Advances, Lung Cancer Research Studies, Neuroblastoma Research and Treatments, and Pancreatic and Hepatic Oncology Research.
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Association Between Long-Term Proton Pump Inhibitor Use and Low-Risk Gastric Neuroendocrine Tumors.
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC).
NETest® 2.0-A decade of innovation in neuroendocrine tumor diagnostics.
Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy
Somatostatin Receptor Expression of Gastroenteropancreatic Neuroendocrine Tumors: A Comprehensive Analysis in the Era of Somatostatin Receptor PET Imaging.
Emerging Diagnostics and Therapies in Neuroendocrine Neoplasms: A Critical Review.
Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
The exceptionally rare phenomenon of well-differentiated colon neuroendocrine tumors.
Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with <sup>177</sup>Lu-DOTATATE.
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors.
Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer.
Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors.
Surgical management of metastatic neuroendocrine tumors: beyond the realm of evidence-based medicine.
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.
ACTH-secreting pancreatic neuroendocrine neoplasms: A case-series.
The Future of Targeted α-Therapy Is Bright, but Rigorous Studies Are Necessary to Advance the Field.
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.
Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis.
Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review.
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update.